Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast

[News]

Giving a monoclonal antibody (denosumab) as adjuvant therapy with aromatase inhibitors in postmenopausal, hormone-receptor-positive breast cancer patients reduces the relapse rate by 18%. This is the central finding of the ABCSG 18 breast cancer study regarding disease-free survival.

More... (http://www.news-medical.net/news/20151210/Monoclonal-antibody-reduces-relapse-rate-by-1825-in-postmenopausal-HR-positive-breast-cancer-patients.aspx)